Chandipura Virus infection in mice: the role of toll like receptor 4 in pathogenesis
© Anukumar and Shahir; licensee BioMed Central Ltd. 2012
Received: 3 March 2012
Accepted: 2 May 2012
Published: 29 May 2012
The susceptibility of mice and humans to Chandipura virus infection is age-dependent. Upon experimental infection, mice secrete significant amounts of proinflammatory cytokines. Similarly, children who recover from natural infection with the virus show significant amounts of TNF-α production, suggesting that innate immunity plays a major role in the response to Chandipura virus. Toll-like receptors (TLR) are key host molecules involved in innate immune responses in infections. Therefore, the aim of this study was to examine the role of TLR in the response to Chandipura virus infection.
The mouse monocyte-macrophage cell line, RAW 264.7, and C3H/HeJ mice were used as models. Micro array techniques were used to identify the type of TLR involved in the response to infection. The results were validated by examining TLR expression using flow cytometry and by measuring the levels of proinflammatory cytokines and nitric oxide (NO) in the culture supernatants using bead assays and the Griess method, respectively. The pathogenic role of Toll-like receptor 4 (TLR4) was studied in a TLR4 mutant strain of mice -C3H/HeJ and the results compared with those from wild-type mice- C3H/CaJ. The pathogenic effects of NO were studied by treating experimentally infected mice with the NO inhibitor, aminoguanidine (AG).
The micro array results showed that TLR4 was regulated after Chandipura virus infection. At high multiplicities of infection (10 MOI), RAW cells up- regulated cell surface expression of TLR4 and secreted significant amounts of TNF-α, MCP-1, IL-10 and IL-12 and NO. The survival rate of C3H/HeJ mice was higher than those of wild-type C3H/CaJ mice. The survived C3H/HeJ mice secreted significant quantity of MCP-1 and IFN-γ cytokines and cleared virus from brain. Similarly, the survival rate of AG-treated mice was higher than those of the untreated controls.
Chandipura virus regulates TLR4, which leads to the secretion of proinflammatory cytokines and NO by infected RAW cells. Difference in survival rate in TLR4 mutant mice and nitric oxide inhibitor treated mice, confirmed the role of these molecules in disease pathogenesis. The result is significant in clinical management and designing antiviral intervention for Chandipura virus infection.
Chandipura virus (CHPV) belonging to the family Rhabdovirdae, genus vesiculovirus has been associated with acute and fatal encephalitis of young children in several parts of India [1, 2]. Children under 15 years of age are vulnerable to natural infection, whereas adults are refractory. Similarly, susceptibility studies in mice show that CHPV is lethal to young mice, but adults are only susceptible through the intra-cerebral route of infection . This age-dependent susceptibility is also apparent in nude mice . Further, virus-infected young mice secrete significant amounts of proinflammatory cytokines  and children who have recovered from natural infections secrete significant levels of TNF-α . Taken, together, these observations strongly suggest that innate immunity plays a pivotal role in protection from CHPV infection. The role of innate immunity is critical during early childhood, particularly when humoral and cell mediated immune responses are not fully developed.
Innate immunity is mediated by several mechanisms. Toll-like receptors (TLR) are key host molecules involved in innate immune responses to infection . TLRs were first identified in Drosophila. To date, 13 mammalian TLRs have been identified . Toll pathways are known to respond to Gram positive bacterial and fungal infections, and are essential for anti-viral immunity . In humans, TLR1, TLR2, TLR4, TLR5 and TLR6 are cell membrane-associated, and respond primarily to bacterial surface-related pathogen associated molecular patterns (PAMPs). A second group, comprising TLR3, TLR7, TLR8 and TLR9, is found on the surfaces of endosomes, and responds primarily to nucleic acid-based PAMPs derived from viruses and bacteria. The interaction between TLRs and viral ligands leads to the secretion of both proinflammatory cytokines, type I interferons and nitric oxide (NO) [10, 11]. Recent studies also show that several types of neural tissue cell up-regulate particular TLRs in response to infection . Failure to prevent or control TLR response could lead to exuberant induction of detrimental cytokines. Various experimental mice model suggests that TLR activation promotes protective antiviral immunity in some cases, while exacerbating disease in others . A role of different TLRs in the response to viruses has been established [14–19].
A growing body of evidence indicates that one particular product of the innate immune response, NO, or its derivatives, has inhibitory effects against a variety of viral infections. NO is one of the products of TLR4 stimulation . Nitric oxide synthase (iNOs) mutant mice are more vulnerable to some types of infection than wild-type mice . NO hinders the productive infection of several animal viruses, including herpes simplex virus 1 (HSV1) , ectromelia virus, vaccinia virus (VV) , vesicular stomatitis virus (VSV)  and murine leukemic virus (MLV) . This suggests that NO could be one of the vital factors that enable host innate immune responses to control the initial stages of viral infections within the central nervous system. NO plays a role in host defense mechanisms due to its antibacterial and virustatic properties; however, if NO synthesis is not properly regulated, damage of host cells occurs due to its inherent cytotoxicity .
In the present study, we focused on the types of TLR involved in immune responses to CHPV infection using RAW cells as an in vitro model. The role of TLRs in disease pathogenesis is also investigated in mice. The results identify a role for TLR4 in the response to CHPV infection and its role in disease pathogenesis.
Cells and virus
Vero E6 and RAW 264.7 cell lines were obtained from the National Centre for Cell Science, Pune, India. The cell lines were cultured and maintained in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal calf serum (FCS, Gibco) and antibiotics. The Chandipura virus strain (034267) was originally isolated from the CHPV outbreak in Andhra Pradesh in 2003 . The virus was propagated and titrated in vero E6 cells.
Confluent monolayer of RAW cells (≈106 cells) was infected with CHPV at 107 50% tissue culture infective dose per mL (TCID50/mL). After adsorption for 1- h at 37°C, the cells were washed with PBS and incubated with DMEM for 24 h at 37°C with 5% CO2. Triplicate cultures were harvested at various times from 1 to 24 h post infection (PI); centrifuged for 5 min at 2500 xg, and virus concentration was determined by endpoint dilutions assay. The titer was calculated by the method of Reed and Muench .
Total RNA was isolated from control and infected RAW cells at 5 h PI using an RNeasy mini kit (Qiagen). The quality and integrity of the RNA was checked before labeling using a 2100 Bioanalyzer (Agilent). RNA was labeled by using Agilent Low RNA Input Linear Amplification kit. Hybridization was performed on mouse microarray slides with 22000 prints (G4112A, Agilent). The biological repeat was performed on the same samples. Data were collected from the hybridized slides using GeneSpring GX 7.2 software and normalized using by Per Spot and Per Chip intensity dependent (Lowess) normalization. Up-regulated genes (ratio > 2) and down-regulated genes (ratio < 0.5) were used to calculate -fold changes. Genes showing -fold changes (log2) > 1 (for up-regulated genes) and > −1 (for down-regulated genes) were further analyzed. The significant functional classification of differentially regulated genes was analyzed using the GeneSpring GX 7.2 software ontology browser and differentially regulated genes significantly (P < 0.05) contributing to the pathways was identified. All data were MIAME-compliant and the raw data has been submitted to Gene Expression Omnibus (GEO -NCBI, Acc.No.GSE 13082).
Cell culture dishes containing confluent monolayer of RAW cells were divided into three groups. The first group was treated with different concentrations of LPS (0–1000 ng/dish). The second group was infected with different MOI of virus (10, 1, or 0.1). The third group was used as uninfected control. All dishes were incubated for 24 h at 37°C with 5% CO2. The cells were then washed with PBS and scraped. Single cell suspensions were produced by slow pipetting, and the cells were pelleted by centrifugation at 300 ×g for 10 min. One million cells were suspended in 100 μL of FACS staining buffer (PBS pH 7.2, 2% FCS, 0.09% sodium azide, 1% mouse serum) and stained with an anti mouse TLR4/MD2 antibody conjugated to phycoerythrin-cyanine 7 (PE-Cy7) (eBioscience). Appropriate isotype controls were included to set the base line data. After 1-h incubation at 4°C, the cells were washed thrice with staining buffer and the pellet suspended in 500 μL of 1% paraformaldehyde. The cells were acquired and analyzed using a FACSCalibur cell sorter and Cell Quest Pro software (BD Bioscience).
Half-offset histograms were prepared using Flow Jo software (Tree Star, USA).
Quantification of mouse inflammatory cytokines
The levels of IL-12p70, TNF-α, IFN-γ, MCP-1, IL-10 and IL-6 in the cell culture supernatants were quantified using a BD™ Cytometric Bead Array (CBA) mouse inflammation kit (BD Biosciences). The minimum/maximum sensitivity of this assay is 0–5000 pg/mL. The levels of the six cytokines were measured simultaneously in 50 μL of undiluted culture supernatant and expressed as pg/ml.
The pathogenicity study was conducted in C3H/HeJ and C3H/CaJ mice. Groups of mice (13-days-old) were used in this experiment (n = 8, plus the mother per group). The experimental procedure was followed as per the recommendations of the Committee for the Purpose of Control and Supervision on Experiments on Animals (CPCESA), India and the protocol was approved by the Institute Animal Ethics Committee (IAEC), National Institute of Virology, Pune. All efforts were made to minimize suffering. Both C3H/HeJ and C3H/CaJ mice were infected with 100 μL (105 TCID50/mL) of CHPV via the subcutaneous route. The mice were observed for sickness and mortality up to 10 days PI. Blood and brain was collected at 0, 24, 48, 72 and 96 h PI. Blood was collected intra orbitally before sacrifice and the sera were separated. Mice were perfused transcardially with 20 mL of PBS and the brain was collected and frozen immediately at −80°C. Before use, the frozen brain was freeze thawed and 10% homogenate prepared in PBS. The suspension was clarified at 1000 ×g for 10 min and the virus in the supernatant was titrated. Cytometric bead array was performed from 50 μL of undiluted serum.
IgM capture ELISA was done following procedure described for human  with the modification that coating was done with anti-mouse IgM as a capture antibody. The level of IgM was determined from 1/100 diluted samples. The cut off value was set by average plus 3 standard deviation of optical density (OD) from uninfected negative control mice.
Quantification of nitric oxide
The cells were infected with different MOI (0.1, 1, and 10 MOI) of virus and the supernatants harvested at 24 h PI. NO levels were measured using the Griess method . Briefly, 100 μL of Griess reagent (1% sulfanilamide, 0.1% naphthylethylene diamine dihydrochloride, 2.5% H3PO4) was added to 100 μL of cell supernatant in a 96-well plate. The colorimetric reaction was allowed to proceed for 10 min at room temperature and the OD at 540 nm (with a reference wavelength of 655 nm) was measured in a micro plate reader (Model 680 XR, BioRad). The measured OD values were converted to equivalent concentrations using a standard curve established from serial dilutions of sodium nitrite (NaNO2) in culture medium. All the samples were assayed in triplicate.
NO inhibitor treatment
Swiss albino mice (13-days-old) were divided into two groups (n = 8, plus the mother per group). Both the groups of mice were infected with 100 μL (105 TCID50/mL) of CHPV via the subcutaneous route. One group was injected with 100 μL (100 mg/kg body weight) of aminoguanidine (AG), and the other was used as a virus control.Treatment started at 24 h PI and continued up to 120 h PI. The mortality pattern was recorded and the percentage mortality calculated.
The Student t test was used to compare the means values for the treated and control groups. A P value < 0.05 was considered significant. The mean survival time was calculated using Kaplan Meier statistics for survival function (GraphPad prism 5 and PASW Statistics 18 software).
One-step growth cycle of CHPV
Regulation of TLR4 by CHPV
Genes involved in different signaling pathways within Chandipura virus infected RAW cells
Path ways involving up-regulated genes
Toll-like receptor signaling pathway
Cytokine-cytokine receptor interaction
MAPK signaling pathway
Antigen processing and presentation
Jak-STAT signaling pathway
T cell receptor signaling pathway
Path ways involving down-regulated genes
Selenoamino acid metabolism
Chondroitin sulfate biosynthesis
Insulin signaling pathway
TLR4 in disease pathogenesis
Nitric oxide in disease pathogenesis
In the current study, the role of TLRs in the response to CHPV in RAW cells was examined. RAW 264.7 cells express various TLRs and have a high sensitivity to TLR ligands . We demonstrate that CHPV infection regulates the TLR4 during infection in RAW cells and TLR4 and NO involved in disease pathogenesis in mice.
TLR4 is involved in LPS signaling and senses Gram negative bacteria [30, 31]. The role of TLR4 in LPS signaling has been reviewed in detail elsewhere [32, 33]. The first indication that TLR4 was involved in the response to viral infection came from research on RSV  and VSV . We compared our results with available literature on vesicular stomatitis virus and other viruses. In experimental HSV-1 infection in TLR2 knockout mice, it was reported that TLR2 mediated cytokine response in the brain contributes to the death of the mice . In our study, we used TLR4 mutant, C3H/HeJ mice to demonstrate the role of TLR4 in disease pathogenesis. C3H/HeJ mice are highly resistant to LPS, showing no usual biological effects, yet, they show a normal response to other bacterial products and to most cytokines induced by LPS. The LPS-resistant phenotype results from defects in the gene for TLR4 (Tlr4) [30, 31]. The percentage survival rate and mean survival time was significantly higher in TLR4 mutant C3H/HeJ mice as compared to those in wild type C3H/CaJ mice. Initially, we suspect that a proinflammatory cytokines level is associated with C3H/HeJ survival. In order to confirm that six signature proinflammatory cytokines in infected C3H/HeJ and C3H/CaJ mice were quantified. Interestingly, the level of MCP-1 and IFN-γ was significantly higher in CHPV infected C3H/HeJ mice than those in infected C3H/CaJ mice.
The role of MCP-1 in protection against virus infection was well documented in influenza virus infection in mice model . The authors opined that lack of MCP-1 responsible for increased virus load in virus infected mice. In our different study, it was observed that high level of MCP-1 in patients recovered from CHPV infection (data not shown). Similarly IFN-γ is reported to be a critical antiviral mediator to eliminate the virus from CNS . IFN-γ treatment at early stage of influenza virus infection protects mice from death . IFN-γ effectively inhibits the replication of VSV in neuronal cells . These cytokines might contribute increase in survival rate in C3H/HeJ mice. These findings could be verified by experimental animal model using MCP-1 and IFN-γ deficient mice. In the current study, there was no significant difference in the level of virus specific antibodies between C3H/HeJ and C3H/CaJ mice which eliminate the possibility of difference in level of antibodies in protection against CHPV infection.
It was reported that IFN-γ treatment enhances the secretion of NO in VSV infected neuronal cells which inhibit the virus replication . In this study, we demonstrate that CHPV infection in RAW cells induced NO secretion. As the NO inhibits the virus replication, it was thought that NO inhibitor (AG) treatment may increase the severity of pathogenesis in infected mice. Conversely, partial protection was observed in treated mice. Thus, we concluded that NO may contribute to the pathogenesis and mortality in infected mice.
Chandipura virus activates TLR4, which leads to the secretion of proinflammatory cytokines and NO. Despite activation of the innate immune system, mortality observed in young mice. Partial protection in TLR4 mutant mice and nitric oxide inhibitor treated wild-type mice indicated that TLR4 and NO contributed in disease pathogenesis. These results are significant in clinical management and designing antiviral intervention.
This work was supported by Department of Biotechnology and Indian council of Medical Research through an in house grant. We thank Drs. A. C. Mishra, K. Alagarasu and M.A. Ramakrishnan for critical review of manuscript.
- Chadha MS, Arankalle VA, Jadi RS, Joshi MV, Thakare JP, Mahadev PVM, Mishra AC: An outbreak of Chandipura virus encephalitis in the eastern districts of Gujarat state, India. Am J Trop Med. 2005, 73: 566-570.
- Rao BL, Basu A, Wairagkar NS, Gore MM, Arankalle VA, Thakare JP, Jadi RS, Rao KA, Mishra AC: A large outbreak of acute encephalitis with high fatality rate in children in Andra pradesh, India, in 2003, associated with Chandipura virus. Lancet. 2004, 364: 869-874.View ArticlePubMed
- Bhatt PN, Rodrigues FM: Chandipura virus: a new arbovirus isolated in India from patients with febrile illness. Indian J Med Res. 1967, 55: 1295-1305.PubMed
- Jortner BS, Bhatt PN, Solitare GB: Experimental Chandipura virus infection in mice. I. Virus assay and light microscopic studies with emphasis on neuropathologic observations. Acta Neuropathol. 1973, 23: 320-325.View ArticlePubMed
- Anukumar B, Mishra AC: Immune response during acute Chandipura viral infection in experimentally infected susceptible mice. Virol J. 2008, 5: 1-11.View Article
- Anuradha T, Balaji S, Rao N, Thakare J, Mishra AC, Arankalle V: Cytokine levels in Chandipura virus associated encephalopathy in children. Scand J Infect Dis. 2005, 37: 590-593.View Article
- Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell. 2006, 124: 783-801.View ArticlePubMed
- Beutler B: Innate immunity: an overview. Mol Immunol. 2004, 40: 845-859.View ArticlePubMed
- Zambon RA, Nandakumar M, Vakharia VN, Wu LP: The Toll pathway is important for an anti-viral response in Drosophila. Proc Natl Acad Sci U S A. 2005, 102: 7257-7262.PubMed CentralView ArticlePubMed
- Seth RB, Sun L, Chen ZJ: Anti-viral innate immune pathways. Cell Res. 2006, 16: 141-147.View ArticlePubMed
- Takeda K, Akira S: Innate immune recognition of viral infection. Nat Immunol. 2006, 7: 131-137.
- Hanisch UK, Johnson TV, Kipnis J: Toll-like receptors: roles in neuroprotection?. Trends Neurosci. 2008, 31: 176-182.View ArticlePubMed
- Thompson JM, Iwasak A: Toll-like receptors regulation of viral infection and disease. Adv Drug Deliv Rev. 2008, 60 (7): 786-794.PubMed CentralView ArticlePubMed
- Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000, 1: 398-401.View ArticlePubMed
- Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA: Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus. J Virol. 2001, 75: 10730-10737.PubMed CentralView ArticlePubMed
- Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW: Human Cytomegalovirus Activates Inflammatory Cytokine Responses via CD14 and Toll-Like Receptor 2. J Virol. 2003, 77: 4588-4596.PubMed CentralView ArticlePubMed
- Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, Ter Meulen V, Schneider-Schaulies S: Hemagglutinin Protein of Wild-Type Measles Virus Activates Toll-Like Receptor 2 Signaling. J Virol. 2002, 76: 8729-8736.PubMed CentralView ArticlePubMed
- Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-B by Toll-like receptor 3. Nature. 2001, 413: 732-738.View ArticlePubMed
- Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A: Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med. 2003, 198: 513-520.PubMed CentralView ArticlePubMed
- Fernandez-Lizarbe S, Pascual M, Gascon MS, Blanco A, Guerri C: Lipid rafts regulate ethanol-induced activation of TLR4 signaling in murine macrophages. Mol Immunol. 2008, 45: 2007-2016.View ArticlePubMed
- Nathan C: Natural resistance and nitric oxide. Cell. 1995, 82: 873-876.View ArticlePubMed
- Croen KD: Evidence for an antiviral effect of nitric oxide: inhibition of herpes simplex virus type-1 replication. J Clin Invest. 1993, 91: 2446-2452.PubMed CentralView ArticlePubMed
- Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD: Inhibition of viral replication by interferon-g-induced nitric oxide synthase. Science. 1993, 261: 1445-1448.View ArticlePubMed
- Cseh K, Beutler B: Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein. J Biol Chem. 1989, 264: 16256-16260.PubMed
- Akarid K, Sinet M, Desforges B, Gougerot-Pocidalo MA: Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. J Virol. 1995, 69: 7001-7005.PubMed CentralPubMed
- Wong JM, Billiar TR: Regulation and function of inducible nitric oxide syntase during sepsis and acute inflammation. Adv Pharmacol. 1995, 34: 155-170.View ArticlePubMed
- Reed LJ, Muench H: A simple method of estimating fifty percent end points. Am J Hyg. 1938, 27: 493-497.
- Gresser I, Tovey MG, Maury C, Bandu MT: Role of interferon in the pathogenesis of virus diseases as demonstrated by the use of anti interferon serum II. Studies with herpes simplex, Molney sarcoma, vesicular stomatitis, Newcastle disease and influenza viruses. J Exp Med. 1976, 144: 1316-1323.View ArticlePubMed
- Applequist SE, Wallin RP, Ljunggren HG: Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol. 2002, 14: 1065-1074.View ArticlePubMed
- Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science. 1998, 282: 2085-2088.View ArticlePubMed
- Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda Y, Akira S: Toll-like receptor 4 (TLR4)-deficient mice are hypo responsive to lipopolysaccaride: evidence for TLR4 as the Lps gene product. J Immunol. 1999, 162: 3749-3752.PubMed
- Yong-Chen Lu, Yeh W-C, Ohashi PS: LPS/TLR4 signal transduction pathway. Cytokine. 2008, 42: 145-151.View Article
- Kawai T, Akira S: TLR signaling. Cell Death Differ. 2006, 13: 816-825.View ArticlePubMed
- Monick MM, Yarovinsky TO, Powers LS, Butler NS, Brent Carter A, Gudmundsson G, Hunninghake GW: Respiratory Syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem. 2003, 278: 53035-53044.View ArticlePubMed
- Georgel P, Jiang Z, Kunz S, Janssen E, Mols J, Hoebe K, Bahram S, Oldstone MBA, Beutler B: Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor4-dependent pathway. Virology. 2007, 362: 304-313.View ArticlePubMed
- Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, Arnold MM, Knipe DM, Finberg RW: Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A. 2004, 101: 1315-1320.PubMed CentralView ArticlePubMed
- Dessing MC, van der Sluijs KF, Florquin S, van der Poll T: Monocyte chemoattractant protein 1 contributes to an adequate immune response in influenza pneumonia. Clin Immunol. 2007, 125 (3): 328-336.View ArticlePubMed
- Chesler DA, Reiss CS: The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002, 13 (6): 441-454.View ArticlePubMed
- Weiss ID, Wald O, Wald H, Beider K, Abraham M, Galun E, Nagler A, Peled A: IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. J Interferon Cytokine Res. 2010, 30 (6): 439-449.View ArticlePubMed
- Chesler DA, Dodard C, Lee GY, Levy DE, Reiss CS: Interferon-gamma-induced inhibition of neuronal vesicular stomatitis virus infection is STAT1 dependent. J Neurovirol. 2004, 10 (1): 57-63.View ArticlePubMed
- D'Agostino PM, Yang J, Reiss CS: Distinct mechanisms of inhibition of VSV replication in neurons mediated by Type I and Type II IFN. Virus Rev Res. 2009, 14 (2): 20-29.PubMed CentralPubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/12/125/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.